Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: polytope monoclonal antibody therapeutics - ImmunoPrecise Antibodies

Drug Profile

Research programme: polytope monoclonal antibody therapeutics - ImmunoPrecise Antibodies

Latest Information Update: 30 Jun 2020

At a glance

  • Originator EVQLV; ImmunoPrecise Antibodies
  • Class Antivirals; Monoclonal antibodies; Viral vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 22 Jun 2020 ImmunoPrescise Antibodies and LiteVax agree to conduct preclinical trials of polytope vaccine candidates for COVID-2019 infections
  • 18 Mar 2020 Early research in Coronavirus infections in USA (Parenteral) (ImmunoPrecise Antibody Website, March 2020)
  • 17 Mar 2020 ImmunoPrecise Antibodies and EVQLV entered into research collaboration to develop lead therapeutic and vaccine candidate against SARS-CoV-2 coronavirus infection

Development Overview

Introduction

Polytope monoclonal antibody vaccine candidates are being developed by ImmunoPrecise Antibodies (IPA) in collaboration with EVQLV for the treatment of COVID-19 infections. EVQLV, an artificial intelligence company will utilise B cell selectTM and custom DeepDisplayTM platform developed at IPA. B cell selectTM platform enables the interrogation of B-cells and generate native monoclonal antibodies from any immunised animal, independent of species. DeepDisplayTM platform is a combination of phage display platform which contains immune libraries from different animal species including transgenic animals and Ligand's OmniAb therapeutic antibody platform which develop fully human antibody with reduced immunogenicity. EVQLV will perform in-silico antibody design to discover novel antibody sequence to leverage lead candidate from IPA's discovery platform. Early research is underway in US.

Company Agreements

In June 2020, ImmunoPrecise Antibodies (IPA) entered into collaboration with LiteVax to conduct preclinical study to determine the immunogenicity, safety and potency of IPA’s novel SARS-CoV-2 vaccine candidates, when formulated with LiteVax’s adjuvant (LVA). The study will be conducted in a swine animal model. Both parties will retain full rights to their respective proprietary assets and know-how used for the study. If the preclinical study is successful, IPA and LiteVax may then negotiate the terms for a preclinical study in a second animal model, as well as details of potential commercialisation of any resulting vaccine. Financial details were not disclosed. [1]

In March 2020, ImmunoPrecise Antibody and EVQLV entered into research collaboration to develop lead therapeutic and vaccine candidate against COVID-19. Under the terms of the agreement, EVQLV will perform in silico antibody design and discovery to generate novel, optimized antibody sequences leveraging lead candidate data from IPA’s discovery technologies, as well as previously published sequences. EVQLV will utilise its in-silico antibody design to generate novel antibody sequence by using IPA's B cell selectTM and custom deep displayTM technology platform to discover lead candidate against SARS-CoV-2 coronavirus infection.

Key Development Milestones

In June 2020, ImmunoPrecise Antibodies announced that they intend to conduct preclinical trial with polytope monoclonal antibody candidates in collaboration with LiteVax in August 2020. The preclinical study will determine immunogenicity, safety and potency of the candidates with an adjuvant provided by LiteVax. The study will be funded by TRANSVAC2 [1] .

In March 2020, EVQLV submitted the first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2 [2] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antivirals, Monoclonal antibodies, Viral vaccines
  • Target Undefined
  • Mechanism of Action Immunomodulators
  • WHO ATC code

    J05A-X (Other antivirals)

  • EPhMRA code

    J5B (Antivirals, excluding anti-HIV products)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research USA Parenteral / unspecified EVQLV, ImmunoPrecise Antibodies 18 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
EVQLV Originator USA
ImmunoPrecise Antibodies Originator Canada
EVQLV Owner USA
ImmunoPrecise Antibodies Owner Canada
LiteVax BV Collaborator Netherlands

Development History

Event Date Update Type Comment
22 Jun 2020 Licensing Status ImmunoPrescise Antibodies and LiteVax agree to conduct preclinical trials of polytope vaccine candidates for COVID-2019 infections [1] Updated 30 Jun 2020
18 Mar 2020 Phase Change Early research in Coronavirus infections in USA (Parenteral) (ImmunoPrecise Antibody Website, March 2020) Updated 26 Mar 2020
17 Mar 2020 Licensing Status ImmunoPrecise Antibodies and EVQLV entered into research collaboration to develop lead therapeutic and vaccine candidate against SARS-CoV-2 coronavirus infection Updated 26 Mar 2020

References

  1. Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2.

    Media Release
  2. ImmunoPrecise's Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody Sequences to Coronavirus for PolyTope(TM) mAb Therapy Program.

    Media Release
Back to top